Company Filing History:
Years Active: 2006
Title: Abraham M De Vos: Innovator in Vascular Biology
Introduction
Abraham M De Vos is a notable inventor based in Oakland, CA (US). He has made significant contributions to the field of vascular biology, particularly through his innovative work on vascular endothelial cell growth factor (VEGF) variants. His research has implications for various medical applications, including treatments for diseases related to blood vessel formation.
Latest Patents
Abraham M De Vos holds a patent for "Vascular endothelial cell growth factor variants and uses thereof." This invention provides VEGF variants that have one or more amino acid mutations in the KDR and/or FLT-1 receptor binding domains in the native VEGF sequence. These variants exhibit selective binding affinity for either the KDR receptor or the FLT-1 receptor. The patent also outlines methods for making these VEGF variants and their potential uses in medical treatments.
Career Highlights
Abraham M De Vos is associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Brian C Cunningham and Bing Li. Their collaborative efforts have further advanced the understanding and application of VEGF variants in medical science.
Conclusion
Abraham M De Vos is a distinguished inventor whose work on VEGF variants has the potential to impact the field of vascular biology significantly. His contributions continue to pave the way for advancements in medical treatments related to blood vessel formation.